Ezh2 inhibiting combination therapies for treatment of cancers
Patent Information
- Application Number
- JP2024120721
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-07-24
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-07-23
Smart Images

Figure 2024156753000007 
Figure 2024156753000008 
Figure 2024156753000009
Abstract
Description
Related Applications
[0001] This application claims priority to U.S. Provisional Application No. 62 / 878,021, filed July 24, 2019, the entire contents of which are incorporated herein by reference. [Background technology]
[0002] Enhancer of Zeste Homolog 2 (EZH2) is a histone lysine methyltransferase that is involved in the pathogenesis of both hematological and non-hematological malignancies. EZH2 catalyzes the transfer of one, two, and three methyl groups to lysine 27 of histone 3 (H3K27). EZH2 is a catalytic component of a large multiprotein complex called Polycomb Repressive Complex 2 (PRC2), which generally functions in transcriptional repression (Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life.Nature 469,343-349). In many cases, transcriptional silencing by PRC2 depends on the catalytic activity of EZH2, but it is clear that physical association of the PRC2 complex with specific genes is also important for transcriptional repression. Alternatively, the PRC2 complex may contain a closely related homolog of EZH2 known as EZH1. These two catalytic subunits of the PRC2 complex are the only enzymes known to catalyze H3K27 methylation. EZH1 and EZH2 are multi-domain proteins that, in addition to their catalytic activity, mediate other biological effects through protein-protein and protein-nucleic acid interactions. H3K27 dimethylation and trimethylation (H3K27me2 and H3K27me3) are well correlated with transcriptionally repressed genes, whereas H3K27 monomethylation (H3K27me1) is found on transcriptionally active genes (Barski, A., et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837, Ferrari, KJ, et al. (2014). Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity. Mol. Cell 53, 49-62). Recent genetic studies suggest that EZH1-containing PRC2 regulates H3K27me1 levels (Hidalgo, I., et al. (2012). Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell 11, 649-662, Xie, H., et al. (2014). Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 14, 68-80). This is consistent with a putative role for EZH1 in transcription elongation (Mousavi, K., et al. (2012). Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol. Cell 45, 255-262). Thus, PRC2-dependent H3K27 methyltransferase activity is involved in both transcriptional repression and activation, depending on the composition of the complex.
[0003] EZH2 (but not EZH1) is frequently overexpressed in human cancers. The molecular basis of EZH2 overexpression in cancer includes (1) genomic amplification of the locus of the gene encoding EZH2 (Tiffen, J., et al. (2016). Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.Neoplasia 18(2),121-132.,Ding,L.,et al.(2006).Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.Cancer Research 66(8),4095-4099.,Saramaki,OR,et al.(2006).The gene for polycomb group protein enhancer of zeste homolog 2(EZH2)is amplified in late-stage prostate cancer.Genes Chromosomes Cancer 45(7),639-645.), (2) deletion and epigenetic silencing of microRNAs that attenuate EZH2 expression (Varambally,S.,et al.(2008).Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.Science 322(5908),1695-1699), and (3) dysregulation of gene regulation exerted by the E2F family of transcription factors (Santos,M.,et al.(2014).In in vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.Cancer Research 74(22),6565-6577.,Coe,BP,et al.(2013).Genomic deregulation of the E2F / Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.PLoS One 8(8),e71670.,Bracken,AP,et al.(2003).EZH2 is downstream of the pRB-E2F pathway,essential for proliferation and amplified in cancer.EMBO J 22(20),5323-5335), including, for example, in terms of deletion of the RB1 gene. Thus, there are several recurrent genomic abnormalities in cancer that cause EZH2 overexpression, proving that increased EZH2 levels promote tumor progression. To this end, EZH2 has been linked to numerous cancer targets, such as hematological malignancies and solid tumors. See, for example, WO2014 / 124418.
[0004] An EZH2 inhibitor that has attracted attention due to its antitumor activity and long residence in the PRC2 complex (about 101 days) is 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide. See, for example, PCT / US2019 / 027932, the contents of which are incorporated herein by reference. Given its therapeutic potential and the prevalence of diseases such as cancer, there is a need for alternative therapeutic uses for this compound, for example, for use in combination-based therapy. Summary of the Invention
[0005] 7-Chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide Provided herein are methods of treating cancer using an amide, or a pharma- ceutically acceptable salt thereof, and a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.
[0006] Also provided herein is a method of treating advanced recurrent solid tumors using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, as monotherapy.
[0007] Also provided herein is a pharmaceutical composition comprising 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, and a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor, and, optionally, a pharma- ceutically acceptable carrier. [Brief description of the drawings]
[0008] [Figure 1A] Phenotypic response of cisplatin-sensitive and -resistant A2780 (ovarian cancer) and HT1376 (bladder cancer) cell lines to a single treatment with cisplatin. Data shown are mean cell viability ± standard error of the mean (SEM), n = 2–3, representative of independent experiments in replicates. [Figure 1B]Figure 1 shows the phenotypic response of cisplatin-sensitive and -resistant A2780 (ovarian cancer) and HT1376 (bladder cancer) cell lines to a single treatment with compound 1. Data shown are mean cell viability ± standard error of the mean (SEM), n = 2-3, and representative of independent experiments in replicates. [Figure 2A] Representative growth curves are shown for cisplatin alone and in combination with a dose titration of compound 1 in cisplatin-sensitive and -resistant A2780 ovarian cancer cell lines. Representative of replicate independent experiments, mean ± SD is shown. [Figure 2B] 1 shows the sub-GI50 dose for cisplatin in A2780-P and A2780-CR in combination with a sub-GI50 dose of 16 nM Compound 1. Representative of replicate independent experiments, mean ± SD is shown. [Figure 3A] Representative growth curves are shown for cisplatin alone and in combination with a dose titration of compound 1 in cisplatin-sensitive and -resistant HT1376 bladder cancer cell lines. Representative of replicate independent experiments, mean ± SD is shown. [Figure 3B] Figure 1 shows near-GI50 dose combinations for cisplatin and Compound 1 in HT1376-DMF and HT1376-CR. Representative of replicate independent experiments, mean ± SD is shown. [Figure 4] Figure 1 shows the antitumor effect of Compound 1, cisplatin, and the combination of both in HT1376 tumors in CB17 SCID mice. Data shown are mean tumor size ± SEM, n = 6. PO = oral administration, IV = intravenous administration, QD = once a day, QW = once a week. [Diagram 5] Figure 1 shows the antitumor efficacy of Compound 1, Enzalutamide, and the combination of both in the CTG-2428 patient-derived xenograft (PDX) model of prostate cancer. Data shown are mean tumor size ± SEM, n=5 per arm. Arrows indicate unscheduled death or end of animal due to achievement of maximum tumor volume, n indicates remaining animals per arm. PO=oral administration, QD=once daily. [Figure 6] Figure 1 shows the antitumor efficacy of Compound 1, Enzalutamide, and the combination of both in the CTG-2440 PDX model of prostate cancer. Data shown are mean tumor size ± SEM, PO = oral administration, QD = once daily. Arrows indicate the death of animals in the combination arm, causing a reduction in group size, and removal of material from individual animals due to maximum tumor volume, n = remaining animals in the arm. [Figure 7] Figure 1 shows the antitumor effect of Compound 1, Enzalutamide, and the combination of both in the CTG-2441 PDX model of prostate cancer. Data shown are mean tumor size ± SEM, n=5. Arrows indicate animal deaths causing a reduction in group size, n=remaining animals in arm. PO=orally administered, QD=once a day. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] In a first embodiment, a method of treating cancer in a subject is provided, comprising administering to the subject an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, and an effective amount of a second agent selected from a topoisomerase inhibitor and an androgen receptor signaling inhibitor. Alternatively, as part of the first embodiment, there is provided the use of an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, and an effective amount of a second agent selected from a topoisomerase inhibitor and an androgen receptor signaling inhibitor, for the manufacture of a medicament for treating cancer in a subject. In another alternative, as part of the first embodiment, there is provided an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, and an effective amount of a second agent selected from a topoisomerase inhibitor and an androgen receptor signaling inhibitor, for use in treating cancer in a subject.
[0010] 7-Chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide has the following chemical formula: [ka] and is disclosed in International Application No. PCT / US2019 / 027932, the contents of which are incorporated herein by reference. "Compound 1" is used interchangeably with 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, each including stereoisomeric and geometric isomeric forms.
[0011] The topoisomerase inhibitor of this method refers to a chemical or biological agent that blocks the action of topoisomerase (including topoisomerase I and II). As an alternative, as part of a second embodiment, the topoisomerase inhibitor of the method (such as in the first embodiment) includes, but is not limited to, irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticine, aurintricarboxylic acid, HU-331, epirubicin, valrubicin, idarubicin, pixantrone, teniposide, belotecan, gimatecan, indothecan, indimitecan. Alternatively, as part of a second embodiment, the topoisomerase inhibitor of the method (such as in the first embodiment) is a topoisomerase I inhibitor. In another alternative, as part of a second embodiment, the topoisomerase inhibitor of the method (such as in the first embodiment) is irinotecan. In another alternative, as part of a second embodiment, the topoisomerase inhibitor of the method (eg, as in the first embodiment) is topotecan.
[0012] The DNA alkylating agent of the present method refers to a chemical or biological agent that acts by preventing DNA strands from linking together as they should.As part of the third embodiment, the DNA alkylating agent of the present method (e.g., as in the first embodiment) is selected from busulfan, cyclophosphamide, bendamustine, carboplatin, chlorambucil, cyclophosphamide, cisplatin, temozolomide, melphalan, carmustine, lomustine, dacarbazine, oxaliplatin, ifosamide, thiotepa, trabectedin, altretamine, mechlorethamine, procarbazine, and streptozocin.Alternatively, as part of the third embodiment, the DNA alkylating agent of the present method (e.g., as in the first embodiment) is cisplatin.
[0013] The androgen receptor signaling inhibitor of the present method refers to a chemical or biological agent that blocks androgen receptor (AR) and inhibits or suppresses androgen production.As part of the fourth embodiment, the androgen receptor signaling inhibitor of the present method (such as the first embodiment) is selected from bicalutamide, enzalutamide, apalutamide, flutamide, nilutamide, darolutamide, and abiraterone acetate (abiraterone acetate can be included alone or in combination with prednisone).Alternatively, as part of the fourth embodiment, the androgen receptor signaling inhibitor of the present method (such as the first embodiment) is enzalutamide.In another alternative example, as part of the fourth embodiment, the androgen receptor signaling inhibitor of the present method (such as the first embodiment) is abiraterone acetate (abiraterone acetate can be included alone or in combination with prednisone).
[0014] As used herein, the terms "treatment," "treat," and "treating" refer to ameliorating, alleviating, or inhibiting the progression of cancer, or one or more symptoms thereof, as described herein.
[0015] When used to define cancer, the term "advanced," such as "advanced cancer" or "advanced prostate cancer," means that the recited cancer is defined as being unresectable, i.e., the cancer cannot be completely removed by surgery, or the cancer is metastatic, or both. In one embodiment, "advanced cancer" means that the cancer is unresectable.
[0016] The cancers described herein may also be "recurrent" cancers. The term "recurrent cancer" refers to cancers that were previously in remission and have returned, or where signs and symptoms of cancer have returned. Remission includes both partial remission (where some or not all signs and symptoms of cancer have disappeared) and complete remission (where all signs and symptoms of cancer have disappeared, but the cancer may still remain in the body). Thus, "advanced recurrent" cancer means that the cancer was in remission and has returned and is unresectable.
[0017] Exemplary types of cancers treated by the method (e.g., as in the first, second, third, or fourth embodiment) include, for example, adrenal gland carcinoma, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrohidroma, acute eosinophilic leukemia, acute erythroleukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatous odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasms, adrenal cortical carcinoma, adult T-cell leukemia / lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar rhabdomyosarcoma, and / or alveolar leukemia. Focal soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid carcinoma, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear cell sarcoma of the kidney, craniopharyngioma , cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, inclusion fetal tumor, fibroma, fibrosarcoma, follicular lymphoma, thyroid follicular carcinoma, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, male germ cell tumor Cystoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematologic malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor,Mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, mixed Müllerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurilemmoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, eye Cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryomatosis, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, Pseudomyxoma peritonei, Renal cell carcinoma, Renal medullary carcinoma, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter transformation, Rectal cancer, Sarcoma, Schwannomatosis, Seminoma, Sertoli cell tumor, Sex cord stromal tumor, Signet ring cell carcinoma, Skin cancer, Small blue round cell tumor, Small cell carcinoma, Soft tissue sarcoma, Somatostatinoma, Smooth warts, Spinal tumor, Splenic marginal zone lymphoma, Squamous cell carcinoma, Synovial sarcoma, Sezary These include: small intestine cancer, squamous cell carcinoma, gastric cancer, T-cell lymphoma, testicular cancer, thecal cell carcinoma, thyroid cancer, transitional cell carcinoma, laryngeal cancer, urachal cancer, genitourinary cancer, urothelial carcinoma, uveal melanoma, metastatic castration-resistant prostate cancer, ovarian clear cell carcinoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor.
[0018] In one aspect, as part of the fifth embodiment, the cancer treated by the method (such as the first, second, third, or fourth embodiment) is a solid tumor. As presented herein, a solid tumor refers to an abnormal mass of tissue that typically does not contain cysts or liquid areas. Solid tumors may be benign or malignant, and the types of cells that form them may vary. Examples of solid tumors include, for example, sarcomas, carcinomas, and lymphomas.
[0019] In one aspect, as part of the sixth embodiment, the cancer treated by the method (e.g., as in the first, second, third, or fourth embodiment) is a solid malignant tumor. Alternatively, as part of the fifth embodiment, the solid tumor treated by the method (e.g., as in the first, second, third, or fourth embodiment) is selected from bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, uterine cancer, kidney cancer, lip cancer, oral cancer, liver cancer, skin cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, and gastric or gastroesophageal cancer. In another alternative, as part of the sixth embodiment, the solid tumor treated by the method (e.g., as in the first, second, or third embodiment) is selected from prostate cancer, small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer. In another alternative, as part of the sixth embodiment, the solid tumor treated by the method (e.g., as in the first, second, third, or fourth embodiment) is selected from small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer. In another alternative, as part of the sixth embodiment, the solid tumor treated by the method (e.g., as in the first, second, third, or fourth embodiment) is prostate cancer. In another alternative, as part of the sixth embodiment, the solid tumor treated by the method (e.g., as in the first, second, third, or fourth embodiment) is selected from urothelial carcinoma, ovarian clear cell carcinoma, and endometrial carcinoma.
[0020] In one aspect, as part of the seventh embodiment, the cancer treated by the method (e.g., as in the first to sixth embodiments) is a recurrent cancer. Thus, as part of the sixth embodiment, the cancer treated by the method (e.g., as in the first to sixth embodiments) is a recurrent solid tumor, such as recurrent prostate cancer, recurrent small cell lung cancer (SCLC), recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma, and recurrent serous ovarian cancer.
[0021] In one aspect, the cancer described herein (e.g., as in the fourth to seventh embodiments) is an advanced cancer, such as advanced prostate cancer, advanced small cell lung cancer (SCLC), advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, and advanced serous ovarian cancer.
[0022] Unless otherwise indicated, administration as described herein includes administration of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide prior to, concurrently with, or subsequent to administration of a topoisomerase inhibitor or androgen receptor signaling inhibitor disclosed herein (e.g., as in the first, second, third, or fourth embodiments) to treat the listed cancers (e.g., as in the fifth through seventh embodiments). Thus, simultaneous administration is not required for therapeutic purposes. However, in one embodiment, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is administered simultaneously with a topoisomerase inhibitor or an androgen receptor signaling inhibitor.
[0023] In an eighth embodiment, provided herein is a method of treating advanced recurrent solid tumors using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof. Alternatively, one of the seventh embodiments is provided herein. In one embodiment, there is provided the use of an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutical acceptable salt thereof, for the manufacture of a medicament for treating an advanced recurrent solid tumor in a subject. In another alternative, as part of the eighth embodiment, there is provided an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, for use in treating an advanced recurrent solid tumor in a subject.
[0024] Advanced recurrent solid tumors described herein (such as in the seventh embodiment) include, but are not limited to, advanced recurrent urothelial carcinoma, advanced recurrent ovarian clear cell carcinoma, and advanced recurrent endometrial carcinoma.
[0025] In a ninth embodiment, provided herein is a pharmaceutical composition comprising an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, an effective amount of a second agent selected from a topoisomerase inhibitor and an androgen receptor signaling inhibitor, and, optionally, a pharma- ceutically acceptable carrier. Also included is the use of a pharmaceutical composition (e.g., as in the fifth to seventh embodiments) comprising an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, and an effective amount of a second agent selected from a topoisomerase inhibitor and an androgen receptor signaling inhibitor, and, optionally, a pharma- ceutically acceptable carrier, for treating one or more cancers described herein. Further provided is the use of a pharmaceutical composition comprising 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, for treating advanced recurrent solid tumors.
[0026] In one embodiment, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°. Alternatively, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by at least four X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide has at least 5° C. at 2θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by at least six X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 10.2°, 12.3°, 12.7°, 13.3°, 14.9°, 15.3°, 20.2°, 20.8°, 21.3°, 22.2°, 22.5°, and 23.8°.In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 10.2°, 11.0°, 11.4°, 11.8°, 12.3°, 12.7°, 13.3°, 14.9°, 15.3°, 16.1°, 17.4°, 20.2°, 20.8°, 21.3°, 22.2°, 22.5°, and 23.8°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 14.9°, 20.2°, and 20.8°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 14.9°, 20.2°, and 20.8°. In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 14.9°, 20.2°, 20.8°, and 22.2°.In another alternative, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is of crystalline form 1 characterized by X-ray powder diffraction peaks at 2θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, and 22.2°.
[0027] In one embodiment, the 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1 ,3]dioxole-5-carboxamide is (2R)-7-chloro-2-(trans-4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide.
[0028] The term "pharmaceutically acceptable carrier" refers to a non-toxic carrier, adjuvant, or vehicle that does not adversely affect the pharmacological activity of the compound with which it is formulated and that is safe for use in humans. Pharmaceutically acceptable carriers, adjuvants, or vehicles that may be used in the compositions of the present disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, magnesium stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances (e.g., microcrystalline cellulose, hydroxypropylmethylcellulose, lactose monohydrate, sodium lauryl sulfate, and croscarmellose sodium), polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.
[0029] The compounds described herein can exist in the form of pharmaceutically acceptable salts.For use in medicine, the salts of the compounds described herein refer to non-toxic "pharmaceutically acceptable salts".Pharmaceutically acceptable salt forms include, where possible, pharmaceutically acceptable acidic / anionic or basic / cationic salts.
[0030] The compositions and methods of administration herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques.
[0031] It will also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated. The amount of compound provided in the composition will also depend on the particular compound in the composition.
[0032] The terms "subject" and "patient" may be used interchangeably and refer to a mammal in need of treatment, such as companion animals (e.g., dogs, cats, etc.), farm animals (e.g., cows, pigs, horses, sheep, goats, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.). Typically, the subject is a human in need of treatment.
[0033] The term "effective amount" or "therapeutically effective amount" refers to an amount of a compound described herein that will induce a biological or medical response in a subject, e.g., a dosage of 0.01 to 100 mg / kg body weight / day. In one embodiment, an effective amount of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof, and an effective amount of a topoisomerase inhibitor or androgen receptor signaling inhibitor described herein, together, are such as to elicit a combined effect to measurably treat one or more cancers described herein.
[0034] Example The invention will now be illustrated by the following non-limiting examples.
[0035] Compound 1 can be prepared as a single enantiomer, a single geometric isomer using the following procedure.
[0036] Intermediate 1: 7-chloro-2,4-dimethyl-2-(4-oxocyclohexyl)benzo[d][1,3]dioxole-5-carboxylate methyl [ka]
[0037] Step 1: Synthesis of methyl 5-chloro-3,4-dihydroxy-2-methylbenzoate To a solution of methyl 3,4-dihydroxy-2-methylbenzoate (5.11 g, 27.9 mmol) in tetrahydrofuran (199 mL) was added sulfuryl chloride (2.45 mL, 30.6 mmol) dropwise at -20°C. The reaction mixture was stirred at -20°C for 3 h and then quenched with a saturated aqueous solution of ammonium chloride (50 mL). The desired product was extracted with ethyl acetate (25 mL x 3). The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (silica gel, gradient 0% to 60% ethyl acetate in heptane) to give the title compound (4.117 g, 68% yield) as a beige solid. LCMS [M+H] + m / z: calculated 217.0, found 217.1 (Cl isotope pattern).
[0038] Step 2: Synthesis of methyl 7-chloro-2,4-dimethyl-2-(4-oxocyclohexyl)-2H-1,3-benzodioxole-5-carboxylate A mixture of methyl 5-chloro-3,4-dihydroxy-2-methylbenzoate (1.2 g, 5.53 mmol), triruthenium dodecacarbonyl (176 mg, 276 μmol), and triphenylphosphine (145 mg, 553 μmol) was degassed under vacuum and purged with nitrogen (3 cycles). Toluene (8.1 mL) was added and the reaction mixture was heated to reflux for 30 min. A solution of 4-ethynylcyclohexan-1-one (1.34 g, 11.0 mmol) in toluene (17 mL) was then added dropwise and the reaction was stirred at reflux for 23 h. Finally, the reaction mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (silica gel, 0-60% gradient of ethyl acetate in heptane) to give the title compound (1.327 g, 70% yield) as a yellow oil. LCMS [M+Na] + m / z: calculated 361.1, found 361.1 (Cl isotope pattern).
[0039] Step 3: (R)-7-Chloro-2,4-dimethyl-2-(4-oxocyclohexyl) ) Separation of methyl benzo[d][1,3]dioxole-5-carboxylate and (S)-7-chloro-2,4-dimethyl-2-(4-oxocyclohexyl)benzo[d][1,3]dioxole-5-carboxylate A racemic mixture of methyl 7-chloro-2,4-dimethyl-2-(4-oxocyclohexyl)benzo[d][1,3]dioxole-5-carboxylate (4.4 g, 13 mmol) was separated by preparative SFC [column: ChiralPak AY (inner diameter 250 mm × 50 mm, 10 μm) from Daicel Chemical Industries. Mobile phase A: CO 2 / Mobile phase B: 0.1% NH in methanol 4 OH. Isocratic (85% mobile phase A and 15% mobile phase B). Flow rate: 80 mL / min. Column temperature: 40 °C. Intermediate 1 (Peak 1) (unwanted enantiomer / distomer): Retention time = 6.2 min. Recovery = 1.4 g, 4.05 mmol, 31% yield, 90% ee, 98% purity (yellow solid). 1H NMR (400 MHz, chloroform-d) δ 7.48 (s, 1H), 3.78 (s, 3H), 2.44-2.36 (m, 2H), 2.35-2.25 (m, 6H), 2.19 (tdd, J = 2.8, 5.6, 13.1 Hz, 2H), 1.70-1.57 (m, 5H). Intermediate 1 (peak 2) (desired enantiomer / eutomer): retention time = 7.0 min. Recovery = 1.1 g, 3.08 mmol, yield 23.75%, 99% ee, purity 95% (yellow solid). 1 H NMR (400MHz, chloroform-d) δ7.49(s,1H),3.78(s,3H),2.44-2.36(m,2H),2.36-2.25(m,6H),2.20(tdd,J=2.8,5.6,13.1Hz,2H),1.72-1.59(m,5H). SFC analysis method: [Column: ChiralPak AY-3 (inner diameter 150 x 4.6 mm, 3 μm). Mobile phase A: CO 2 / Mobile phase B: 0.05% Et in iPrOH 2 NH. Gradient: 5% to 40% mobile phase B (over 5.5 min). Flow rate: 2.5 mL / min. Column temperature: 40° C.]. Intermediate 1 (Peak 1—Unwanted enantiomer / distomer): Retention time=2.853 min. Intermediate 1 (Peak 2—Desired enantiomer / eutomer): Retention time=2.979 min.
[0040] Intermediate 2: 7-Chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylic acid [ka]
[0041] Step 1: Synthesis of methyl 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate A solution of 3-methoxyazetidine hydrochloride (8 g, 64.75 mmol) and N,N-diisopropylethylamine (12 mL, 68.9 mmol) in methanol (30 mL) was After stirring at room temperature for 30 min, another solution of methyl 7-chloro-2,4-dimethyl-2-(4-oxocyclohexyl)-1,3-benzodioxole-5-carboxylate (Intermediate 1-Peak 2) (4.1 g, 12.10 mmol) in tetrahydrofuran (30 mL) was added. The reaction mixture was stirred at room temperature for 1 h and then cooled to -70 °C. Lithium borohydride (500 mg, 22.96 mmol) was added and the reaction was stirred at -70 °C for 30 min [or until complete consumption of starting material was observed by TLC, ethyl acetate / methanol 5:1]. The two batches of reaction were then combined and quenched with a saturated aqueous solution of ammonium chloride (120 mL) at 0 °C and the desired product was extracted with dichloromethane (200 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (silica gel, gradient of 0% to 14% methanol in dichloromethane) to give the title compound (8.05 g, 67% yield, 83% purity) as a pale yellow oil. A sample (50 mg) was further purified by preparative thin layer chromatography (silica gel, ethyl acetate:methanol 15:1). LCMS [M+H] + m / z: calculated 410.2, measured 410.1. 1 H NMR (400MHz, methanol-d 4 )δ7.39(s,1H),3.95-3.91(m,1H),3.73(s,3H),3.59-3.51(m,2H),3.16(s,3H),2.97(br dd,J=6.4,8.0Hz,2H),2.26(s,3H),2.11-2.02(m,1H),1.91-1.73(m,5H),1.54(s,3H),1.22-1.12(m,2H),0.98-0.86(m,2H).
[0042] Step 2: Synthesis of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylic acid To a solution of methyl 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylate (4 g, 9.75 mmol) in methanol (48 mL) was added a solution of lithium hydroxide hydrate (4.03 g, 96.06 mmol) in water (12 mL). The reaction was stirred at 70° C. for 2 h, then the two batches were combined and concentrated under reduced pressure. Water (50 mL) was added and the pH was adjusted to 6 with a saturated aqueous solution of citric acid at 0° C. The desired product was extracted with a 3:1 mixture of dichloromethane and isopropanol (300 mL×5). The combined organic layers were dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure to give the title compound (6.1 g, crude) as an off-white solid, which was used in the next step without further purification. LCMS [M+H] + m / z: calculated 396.2, measured 396.1. 1 H NMR (400MHz, methanol-d 4 )δ7.07(s,1H),4.05-4.10(m,2H),3.76-3.88(m,1H),3.67(br dd,J=10,3.6Hz,2H),3.22(s,3H),2.71-2.81(m,1H),2.19(s,3H),1.91-1.99 (m,4H),1.75-1.85(m,1H),1.52(s,3H),1.18-1.28(m,2H),1.06-1.14(m,2H). compound 1 [ka]
[0043] To a solution of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxylic acid (intermediate 2 - single enantiomer and geometric isomer) (5 g, 12.63 mmol) in N,N-dimethylformamide (50 mL) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.7 g, 14.99 mmol) and N,N-diisopropylethylamine (11 mL, 63.15 mmol). The mixture was stirred at 20 °C for 30 min, and then 3-(aminomethyl)-6-methyl-4-(methylthio)pyridin-2(1H)-one hydrochloride (intermediate 1) (4.2 g, 19.03 mmol) was added. The reaction mixture was stirred at room temperature for an additional 1.5 hours and then filtered. The filtrate was purified by preparative HPLC [column: Phenomenex Gemini C18 (250 mm x 50 mm, 10 μm), mobile phase A: water (0.04% ammonium hydroxide v / v and 10 mM ammonium bicarbonate) / mobile phase B: acetonitrile. Gradient (75% to 44% mobile phase A / 25% to 56% mobile phase B, >23 min). Column temperature: 30°C] to give the title compound (4.4 g, 60% yield, 96% purity) as a white solid. LCMS [M+H] + m / z: calculated 562.2, measured 562.2. 1 H NMR (400MHz, methanol-d 4 )δ6.91(s,1H),6.29(s,1H),4.50(s,2H),4.01(sextet,J=6Hz,1H),3.58(dd,J=8.8,6.4Hz,2H),3.26(s,3H),2.92-3.02(m,2H),2 .54(s,3H),2.31(s,3H),2.21(s,3H),2.01-2.11(m,1H),1.79-2.00(m,5H),1.62(s,3H),1.19-1.34(m,2H),0.91-1.08(m,2H).
[0044] 1. Primary In Vitro Pharmacology A. Mechanism of Action In biochemical assays, compound 1 inhibits the catalytic activity of wild-type and Y641N mutant EZH2-containing PRC2 complexes, as well as EZH1-containing PRC2 complexes, with half-maximal inhibitory concentration (IC50) values of 0.02 nM and 0.03 nM for wild-type and Y641N mutant EZH2, respectively, and 0.06 nM for EZH1. See, e.g., PCT / US2019 / 027932. The biochemical potency underestimates the true affinity of compound 1, and further characterization of binding by kinetic assays supports an inhibition constant of approximately 0.11 pM for EZH2, and approximately 70-fold selectivity for EZH2 over EZH1. Based on kinetic analysis, compound 1 was determined to bind to PRC2 with a long residence time (approximately 101 days). See, e.g., PCT / US2019 / 027932.
[0045] B. Global H3K27me3 cellular levels and effects on gene expression The ability of compound 1 to reduce global H3K27me3 intracellular levels was evaluated in wild-type EZH2-containing cervical cancer cell line (HeLa). After 4 days of treatment, compound 1 was able to reduce the global level of H3K27me3 to an EC50 of 0.40 nM. See, for example, PCT / US2019 / 027932. Compound 1 was also able to show similar efficacy in other solid tumor cell lines, including bladder cancer (639V and HT1197) and ovarian cancer TOV21G cell lines, with EC50 values of 0.09 nM, 0.14 nM, and 0.26 nM on day 3, respectively.
[0046] The reduction in H3K27me3 levels leads to changes in gene expression. RNA sequencing of bladder cancer cell lines after 4 days of treatment with compound 1 showed significant changes in the expression levels of multiple genes. The main changes were increased gene expression, with very few genes significantly decreased. The increase in gene expression was both dose and time dependent, with increased expression observed at higher concentrations of compound 1 and at later time points. This is in contrast to the reduction in H3K27me3, as changes in methyl marks were observed 1 day after treatment with compound 1. Notably, one of the highly upregulated genes was CDKN1C (also known as p57 or Kip2), a known tumor suppressor and negative regulator of the cell cycle previously reported to be an EZH2 target gene. See Yang X,Karuturi RK,Sun F,et al.CDKN1C(p57)is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.PLoS One.2009;4(4):e5011.Low expression of CDKN1C is seen in advanced bladder and breast cancer and correlates with poor prognosis.See Yang above and Hoffmann MJ,Florl AR,Seifert HH,et al.Multiple mechanisms downregulate CDKN1C in human bladder cancer.Int J Cancer.2005 Apr 10;114(3):406-13.
[0047] 2. Antiproliferative effects A. Synergism between Compound 1 and Cisplatin (a DNA alkylating agent) We assessed the sensitivity of multiple solid tumor cancer cell lines to the antiproliferative activity of Compound 1 with or without cisplatin. We first found that the cisplatin-resistant forms of the ovarian cancer cell line A2780 (A2780-CR) and bladder cancer cell line (HT1376-CR) were less sensitive to cisplatin than the parental (A2780-P) or age-matched DMF control (HT1376-DMF) cell lines (see FIG. 1A), whereas the A2780 and We found that cisplatin-resistant forms of HT1376 and HT1376 remained sensitive to Compound 1 (see FIG. 1B). However, combined treatment with Compound 1 and cisplatin resulted in a greater than 50% reduction in growth. See FIG. 2A and FIG. 2B.
[0048] Similar results were seen in HT1376 bladder cancer cell lines. For example, cisplatin-sensitive (-DMF) and -resistant (-CR) HT1376 cell lines showed enhanced effects on cell growth when cisplatin treatment was combined with compound 1. See Figure 3A and Figure 3B. In addition, compound 1 alone and in combination with cisplatin were effective in reducing tumor growth. See Figure 4. Taken together, this data demonstrates that compound 1 can be combined with other chemotherapeutic agents to synergistically treat solid tumors such as bladder and ovarian cancer.
[0049] B. Synergistic effect of compound 1 with enzalutamide (an androgen receptor signaling inhibitor) The antitumor efficacy of compound 1 alone and in combination with the androgen receptor signaling inhibitor enzalutamide was evaluated in CTG 2428 PDX tumors in NOG mice. As shown in Figure 5, the combination of compound 1 and enzalutamide reduces absolute tumor volume better than compound 1 or enzalutamide alone. Similar results were seen in CTG-2440 PDX (Figure 6) and CTG-2441 PDX tumors (Figure 7) in NOG mice. This data establishes that compound 1 can be combined with androgen receptor signaling inhibitors such as enzalutamide to treat solid tumor cancers such as prostate cancer.
[0050] 3. Primary in vivo pharmacology (monotherapy and combination therapy) A Phase 1 / 2 study to evaluate the safety, tolerability, and preliminary clinical activity of Compound 1 monotherapy and in combination with irinotecan in six disease-specific dose expansion cohorts will be conducted according to the general procedures outlined below: Phase 1 will consist of a Compound 1 monotherapy dose escalation and combination therapy (Compound 1 + irinotecan) dose escalation period in patients with advanced recurrent solid tumors, and Phase 2 will include a monotherapy dose escalation and combination therapy dose escalation period in six disease-specific dose expansion cohorts.
[0051] A. Efficacy of single agents Patients enrolled in the following cohorts will receive oral Compound 1 monotherapy: ·Monotherapy dose escalation cohorts in patients with advanced recurrent solid tumors. Dose expansion cohort 1 in patients with urothelial carcinoma. Dose expansion cohort 2 in patients with ovarian clear cell carcinoma. Dose expansion cohort 3 in patients with endometrial carcinoma.
[0052] The study will enroll evaluable patients with advanced solid tumors over two phases. Eligibility includes certain criteria, such as relapse after or progression during standard therapy. Phase 1 is intended to determine the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D) of Compound 1 as monotherapy in patients with advanced solid tumors. Secondary objectives include the safety and tolerability of Compound 1, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of Compound 1, and preliminary clinical activity of Compound 1. Phase 2 is designed to evaluate the antitumor activity of Compound 1 as monotherapy in patients with selected solid tumors (e.g., urothelial carcinoma, ovarian clear cell carcinoma, and endometrial carcinoma).
[0053] Patients enrolled in the monotherapy dose escalation portion of the study will receive Compound 1 once daily (QD) orally (PO) in consecutive 4-week (28-day) cycles. The starting dose is 50 mg. The dose of Compound 1 will be titrated up to 100% until at least one grade 2 study drug-related adverse event (excluding anemia or lymphopenia) is reported, after which the dose of Compound 1 may be titrated up to 40%. Intermediate or additional dose levels may be evaluated if recommended based on review of new safety, PK, or PD data. Compound 1 dose levels above 300 mg QD will be titrated up to 25%.
[0054] B. Effectiveness of Combination Therapy Patients enrolled in the following cohorts will receive oral Compound 1 monotherapy: Combination therapy dose escalation cohorts in patients with advanced recurrent solid tumors Dose expansion cohort 4 in patients with small cell lung cancer (SCLC). Dose expansion cohort 5 in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma. Dose expansion cohort 6 in patients with serous ovarian cancer.
[0055] The study will enroll evaluable patients with advanced solid tumors over the same two phases as the monotherapy doses, except the solid tumors selected are small cell lung cancer, gastric or gastroesophageal junction, and serous ovarian cancer. Eligibility will include specific criteria, such as recurrence after or progression during standard therapy.
[0056] Having described several embodiments of the present disclosure, it is apparent that the inventors' basic examples may be modified to provide other embodiments that utilize the compounds and methods of the present disclosure. It will therefore be appreciated that the scope of the present disclosure is defined by the appended claims, rather than by the specific embodiments represented by way of example.
[0057] The contents of all references cited throughout this application (including literature references, issued patents, published patent applications, and co-pending patent applications) are expressly incorporated herein by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein are given the meaning commonly known to those of ordinary skill in the art.
Claims
1. 1. A method of treating a solid tumor in a subject, comprising administering to the subject an effective amount of a compound having the formula: [Formula 1] or a pharma- ceutically acceptable salt thereof and an effective amount of a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.
2. 2. The method of claim 1, wherein the second agent is an androgen receptor signaling inhibitor.
3. 3. The method of claim 1 or 2, wherein the second agent is an androgen receptor signaling inhibitor selected from bicalutamide, enzalutamide, apalutamide, flutamide, nilutamide, darolutamide, and abiraterone acetate.
4. The method of any one of claims 1 to 3, wherein the second drug is enzalutamide.
5. The method of claim 1 , wherein the second agent is a DNA alkylating agent.
6. 6. The method of claim 1 or 5, wherein the DNA alkylating agent is selected from busulfan, cyclophosphamide, bendamustine, carboplatin, chlorambucil, cyclophosphamide, cisplatin, temozolomide, melphalan, carmustine, lomustine, dacarbazine, oxaliplatin, ifosamide, thiotepa, trabectedin, altretamine, mechlorethamine, procarbazine, and streptozocin.
7. The method of claim 1 or 5, wherein the DNA alkylating agent is cisplatin.
8. The method of claim 1 , wherein the second agent is a topoisomerase inhibitor.
9. The method of claim 1 or 8, wherein the topoisomerase inhibitor is a topoisomerase I inhibitor.
10. 9. The method of claim 1 or 8, wherein the topoisomerase inhibitor is selected from irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticine, aurintricarboxylic acid, HU-331, epirubicin, valrubicin, idarubicin, pixantrone, teniposide, belotecan, gimatecan, indotecan, indimitecan.
11. 10. The method of any one of claims 1, 8, and 9, wherein the topoisomerase inhibitor is irinotecan.
12. The method of any one of claims 1 to 11, wherein the solid tumor is selected from prostate cancer, small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer.
13. The method of any one of claims 1 to 12, wherein the solid tumor is selected from small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer.
14. The method of any one of claims 1 to 12, wherein the solid tumor is prostate cancer.
15. The method of any one of claims 1 to 14, wherein the solid tumor is characterized as an advanced tumor.
16. The method of any one of claims 1 to 15, wherein the solid tumor is characterized as a recurrent solid tumor.
17. The method of any one of claims 1 to 16, wherein the compound is administered simultaneously with the second agent.
18. The compound has the formula: [Case 2] or a pharma- ceutically acceptable salt thereof.
19. A method of treating advanced recurrent solid tumors using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharma- ceutically acceptable salt thereof.
20. 20. The method of claim 19, wherein the advanced recurrent solid tumor is advanced recurrent urothelial carcinoma, advanced recurrent ovarian clear cell carcinoma, or advanced recurrent endometrial carcinoma.
21. The method according to claim 19 or 20, wherein the 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is (2R)-7-chloro-2-(trans-4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide.
Citation Information
Patent Citations
Benzofuran derivative, preparation method thereof and use thereof in medicine
CA3002436A1
Modifiers, compositions, and uses of methyl group modifiers.
JP2015506985A
1,3-benzodioxole derivative
WO2015141616A1
Therapeutic and / or prophylactic agent for adult t cell leukemia / lymphoma
WO2017018499A1
Modulators of methyl modifying enzymes, compositions and uses thereof
WO2019204490A1
